Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 25;30(1):9–21. doi: 10.1111/ene.15593

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Time to confirmed disability progression in the North American (NA) and European (EU) studies with interferon β‐1b (IFNB‐1b) in patients with secondary progressive multiple sclerosis (SPMS) [67]. Confirmed progression was defined as time to a ≥1.0 point increase in Expanded Disability Status Scale (EDSS) sustained for ≥6 months or 0.5 point increase in patients with baseline EDSS of 6.0–6.5. [Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta‐1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63(10):1779–1787. doi:10.1212/01.wnl.0000145561.08973.4f, with permission.]